Russian “Pharmsynthez” after the U.S. Gilead Sciences Inc succeeded for a short time to increase the value of their shares. It was speculative interest from investors after the appearance of public reports on the development of these companies drugs for the treatment of COVID-19, insist analysts. However, in their opinion, many large pharmaceutical companies are not particularly expect to increase their capitalization at the expense of suppression of coronavirus, which is confirmed by the stock prices of most companies.That pandemic coronavirus little impact on the stock’s attractiveness the largest pharmaceutical companies in the world, follows from the analysis conducted by the research centre (IC) “GMP news”. Analysts analyzed the stock prices of 42 companies during the period from December 9, 2019, when it was officially announced the first infected COVID-19 China, 22 April 2020, when many countries began the peak incidence. These quotes were compared with two indices — the S&P 500 (TR) that characterize the state of Affairs in General on the US stock market and Dow Jones U.S. Select Pharmaceuticals Total Return Index (SPTRI) that allows you to track sentiment investors buying stocks of pharmaceutical companies.If on December 9, 2019 SPTRI was 106,59 points and S&P 500 (TR) — 109,25, already on 16 March 2020, this ratio made up of 86.84 points (a drop of 18.5% compared to December) and the S&P 500 (TR) — up to 83,57 (minus of 23.5% over three months). After 20 April, both indices are back to the indicators that were before the pandemic.The index of U.S. pharmaceutical companies increased to 103,66 of the item and in comparison with December 2019, decreased by 2.74%, while the underlying S&P 500 index (TR) rose to 98.2, which is below the pre-crisis value of 10.1%.So, for example, shares of Johnson & Oops 9 December were traded at the exchange for $140,5 per share, March 12 for $125,41 and 14 April — for $146,03. The figure for Roche Holding totaled $303.4 for the same date in December, $274,45 in March and $314,9 in April.The pandemic had almost no effect on the company’s biotech sector involved in the development of drugs against severe diseases, agrees the head of scientific expertise pharmaceutical Fund Inbio Ventures, Ilya is Clear. “Also, the pandemic had hardly any effect on the growth of capitalization of companies that have ready-made drugs (for the treatment of coronavirus.— “Kommersant”)”,— he States.However, analysts have recorded one exception — from Gilead Sciences Inc shares on the stock exchange on 17 April soared to a record $84 per share. The reason for this was data leak about a possible positive result of clinical test of “Ramdevpir” for the treatment COVID-19 (this medication in the Corporation’s portfolio in 2015). “This drug previously developed to treat Ebola, but have not shown consistently effective results”,— says Ilya Clear.On the Russian stock market also witnessed two waves of speculative��’s attacks, and it happened with the shares of “Pharmsynthez”, says the analyst of “freedom Finance” Valery Yemelyanov. According to him, in late January and early February the company’s shares rose 2.2 times, by the middle of March has fallen to the January prices double, then in mid-April again gained more than 100% and are now in a downtrend, losing about 20%. “The reason for such fluctuation was the news that the company is developing a drug for the treatment of CoVid-19″— adds Mr. Emelyanov. But, he claims, despite the situation of the pandemic coronavirus, the world’s pharmaceutical companies understand that COVID-19 for them yet “is not a commercially successful trend.” The drug market now focuses on the preparations of expensive and prolonged treatment, such as cancer, HIV, diabetes, arthritis, concludes the expert, stating that the annual turnover of this market segment worldwide is $7-10 billion. Khalil Aminov